HBK Investments
ATRA icon

HBK Investments’s Atara Biotherapeutics ATRA Stock Holding History

HBK Investments’s Portfolio ATRA Stock Details ATRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-584
Closed -$537K – 1164
2018
Q2 		$537K Buy
584
+65
+13% +$69.8K ﹤0.01% 788
2018
Q1 		$506K Buy
+519
New +$473K ﹤0.01% 768

Other funds holding ATRA

Baupost Group
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BM
Bridger Management New York $150M AUM 17.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Eagle Asset Management
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

HBK Investments's ATRA Position: Q3 2018 in Review

HBK Investments sold out of Atara Biotherapeutics (ATRA) in Q3 2018, closing a stake of 584 shares — an estimated $537K sold.

HBK Investments first reported a position in ATRA in Q1 2018 and held it in 2 quarters. The position peaked at $537K in Q2 2018. 115 funds tracked by Wall St. Rank hold ATRA as of Q3 2018.

  • HBK Investments reported no remaining Atara Biotherapeutics position as of Q3 2018 after selling out during the quarter.
  • HBK Investments sold 584 Atara Biotherapeutics shares in Q3 2018, an estimated $537K.
  • HBK Investments first reported a position in Atara Biotherapeutics in Q1 2018 and held it in 2 quarters.
  • HBK Investments's Atara Biotherapeutics position peaked at $537K in Q2 2018.
  • 115 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q3 2018.

Based on HBK Investments's 13F filing for Q3 2018, filed 14 Nov 2018.